Alternative donor hematopoietic stem cell transplantation

A role for umbilical cord blood transplantation for hematologic malignancies

Laura Newell, Jonathan A. Gutman, Colleen Delaney

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Hematopoietic stem cell transplantation (HSCT) is a widely accepted therapy with potentially curative benefit for patients with benign and malignant hematologic disorders. There are currently three possible sources of allogeneic hematopoietic stem cells (HSCs) - bone marrow, granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood (PBSC), and umbilical cord blood (CB). Donors can be either related or unrelated and must match recipients at human leukocyte antigens (HLA). Based on the average size of American families, and the 25% probability that a given sibling pair will be HLA-matched, it is estimated that approximately 35% of persons in the United States will have an HLA-matched sibling.

Original languageEnglish (US)
Title of host publicationLeukemia and Related Disorders
Subtitle of host publicationIntegrated Treatment Approaches
PublisherSpringer New York
Pages219-249
Number of pages31
ISBN (Electronic)9781607615651
ISBN (Print)9781607615644
DOIs
StatePublished - Jan 1 2012
Externally publishedYes

Fingerprint

Hematopoietic Stem Cell Transplantation
Hematologic Neoplasms
HLA Antigens
Fetal Blood
Transplantation
Tissue Donors
Siblings
Granulocyte Colony-Stimulating Factor
Hematopoietic Stem Cells
Bone Marrow
Therapeutics

Keywords

  • Alternative donor
  • Bone marrow
  • Granulocyte colony-stimulating factor
  • Hematopoietic stem cell transplantation
  • Leukemia
  • Mobilized peripheral blood
  • Stem cells
  • Transplantation
  • Umbilical cord blood

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Newell, L., Gutman, J. A., & Delaney, C. (2012). Alternative donor hematopoietic stem cell transplantation: A role for umbilical cord blood transplantation for hematologic malignancies. In Leukemia and Related Disorders: Integrated Treatment Approaches (pp. 219-249). Springer New York. https://doi.org/10.1007/978-1-60761-565-1_8

Alternative donor hematopoietic stem cell transplantation : A role for umbilical cord blood transplantation for hematologic malignancies. / Newell, Laura; Gutman, Jonathan A.; Delaney, Colleen.

Leukemia and Related Disorders: Integrated Treatment Approaches. Springer New York, 2012. p. 219-249.

Research output: Chapter in Book/Report/Conference proceedingChapter

Newell, L, Gutman, JA & Delaney, C 2012, Alternative donor hematopoietic stem cell transplantation: A role for umbilical cord blood transplantation for hematologic malignancies. in Leukemia and Related Disorders: Integrated Treatment Approaches. Springer New York, pp. 219-249. https://doi.org/10.1007/978-1-60761-565-1_8
Newell L, Gutman JA, Delaney C. Alternative donor hematopoietic stem cell transplantation: A role for umbilical cord blood transplantation for hematologic malignancies. In Leukemia and Related Disorders: Integrated Treatment Approaches. Springer New York. 2012. p. 219-249 https://doi.org/10.1007/978-1-60761-565-1_8
Newell, Laura ; Gutman, Jonathan A. ; Delaney, Colleen. / Alternative donor hematopoietic stem cell transplantation : A role for umbilical cord blood transplantation for hematologic malignancies. Leukemia and Related Disorders: Integrated Treatment Approaches. Springer New York, 2012. pp. 219-249
@inbook{9e5e95c48ddb49a2a3e66ef2507aa5f6,
title = "Alternative donor hematopoietic stem cell transplantation: A role for umbilical cord blood transplantation for hematologic malignancies",
abstract = "Hematopoietic stem cell transplantation (HSCT) is a widely accepted therapy with potentially curative benefit for patients with benign and malignant hematologic disorders. There are currently three possible sources of allogeneic hematopoietic stem cells (HSCs) - bone marrow, granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood (PBSC), and umbilical cord blood (CB). Donors can be either related or unrelated and must match recipients at human leukocyte antigens (HLA). Based on the average size of American families, and the 25{\%} probability that a given sibling pair will be HLA-matched, it is estimated that approximately 35{\%} of persons in the United States will have an HLA-matched sibling.",
keywords = "Alternative donor, Bone marrow, Granulocyte colony-stimulating factor, Hematopoietic stem cell transplantation, Leukemia, Mobilized peripheral blood, Stem cells, Transplantation, Umbilical cord blood",
author = "Laura Newell and Gutman, {Jonathan A.} and Colleen Delaney",
year = "2012",
month = "1",
day = "1",
doi = "10.1007/978-1-60761-565-1_8",
language = "English (US)",
isbn = "9781607615644",
pages = "219--249",
booktitle = "Leukemia and Related Disorders",
publisher = "Springer New York",

}

TY - CHAP

T1 - Alternative donor hematopoietic stem cell transplantation

T2 - A role for umbilical cord blood transplantation for hematologic malignancies

AU - Newell, Laura

AU - Gutman, Jonathan A.

AU - Delaney, Colleen

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Hematopoietic stem cell transplantation (HSCT) is a widely accepted therapy with potentially curative benefit for patients with benign and malignant hematologic disorders. There are currently three possible sources of allogeneic hematopoietic stem cells (HSCs) - bone marrow, granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood (PBSC), and umbilical cord blood (CB). Donors can be either related or unrelated and must match recipients at human leukocyte antigens (HLA). Based on the average size of American families, and the 25% probability that a given sibling pair will be HLA-matched, it is estimated that approximately 35% of persons in the United States will have an HLA-matched sibling.

AB - Hematopoietic stem cell transplantation (HSCT) is a widely accepted therapy with potentially curative benefit for patients with benign and malignant hematologic disorders. There are currently three possible sources of allogeneic hematopoietic stem cells (HSCs) - bone marrow, granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood (PBSC), and umbilical cord blood (CB). Donors can be either related or unrelated and must match recipients at human leukocyte antigens (HLA). Based on the average size of American families, and the 25% probability that a given sibling pair will be HLA-matched, it is estimated that approximately 35% of persons in the United States will have an HLA-matched sibling.

KW - Alternative donor

KW - Bone marrow

KW - Granulocyte colony-stimulating factor

KW - Hematopoietic stem cell transplantation

KW - Leukemia

KW - Mobilized peripheral blood

KW - Stem cells

KW - Transplantation

KW - Umbilical cord blood

UR - http://www.scopus.com/inward/record.url?scp=85028290062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028290062&partnerID=8YFLogxK

U2 - 10.1007/978-1-60761-565-1_8

DO - 10.1007/978-1-60761-565-1_8

M3 - Chapter

SN - 9781607615644

SP - 219

EP - 249

BT - Leukemia and Related Disorders

PB - Springer New York

ER -